Liquid Biopsy Market Insights on Scope and Growing Demands 2022

 According to the market research report Liquid Biopsy Market is expected to reach $2,047.9 Million by 2022 from an estimated $715.7 Million in 2017, at a CAGR of 23.4%.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=13966350

Some of the key factors driving the growth of this market include increasing preference for noninvasive procedures, increasing prevalence of cancer and availability of funding for liquid biopsy R&D.

By clinical application, the therapy selection segment is expected to account fors the largest market share in 2017.

Based on clinical application, the liquid biopsy market is segmented into early cancer screening, therapy selection, treatment monitoring, and recurrence monitoring. The therapy selection segment is expected to account for the largest share of the liquid biopsy devices market in 2017. This is due to the ability of therapy selection to detect advanced-stage cancers (stage III and IV), followed by increasing studies on liquid biopsy and advancements made in this field to also aid in detection of early-stage cancers.

By application, the cancer segment is expected to account for the largest market share in 2017. Based on application, the market is segmented into cancer and non-cancer applications (which includes reproductive health and organ transplant diagnostics). In 2017, cancer applications segment is expected to account for the largest share of the liquid biopsy market.

By circulating biomarkers, circulating tumor cells is expected to account for the largest market share in 2017. Based on circulating biomarkers the market is categorized into circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), extracellular vesicles (EVs), and other circulating biomarkers. In 2017, the circulating tumor cells segment is expected to account for the largest share of the liquid biopsy market.

By product, the assay kits segment is expected to account for the largest share of the market in 2017. On the basis of product, the market is broadly segmented into assays kits, instruments, and services. In 2017, the assay kits segment is expected to account for the largest share of this market.

Based on end user, the liquid biopsy market is segmented into reference laboratories, hospitals and physician laboratories, academic and research centers, and other end users (public health laboratories, pathology laboratories, and small molecular laboratories). Reference laboratories form the largest and fastest-growing end-user segment of the liquid biopsy market. The can be attributed to the large volume of tests being outsourced to reference laboratories from oncologists and hospitals.

North America is expected to account for the largest share of the global liquid biopsy market in 2017, while Asia Pacific is expected to witness the highest growth during 2017 to 2022. Growing demand for non-invasive treatment, rising incidence of cancer, and improving healthcare infrastructure are driving the growth of the liquid biopsy market.

The key players in the global liquid biopsy market are QIAGEN N.V. (Netherlands), Roche Diagnostics (US), Bio-Rad Laboratories Inc. (US), Myriad Genetics, Inc. (US), Menarini Silicon Biosystems (Italy), Genomic Health, Inc. (US), Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), Biocept, Inc. (US), Trovagene, Inc. (US), Guardant Health, Inc. (US), RainDance Technologies, Inc. (US), and MDx Health SA (US).

Request For Report Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=13966350

Recent Developments

> In March 2017, QIAGEN N.V. (Netherlands) launched AdhaTest Prostate Cancer Panel AR-V7. AdnaTest Prostate Cancer Panel AR-V7 A are used to detect the androgen receptor splice variant 7 (AR-V7) from liquid biopsies to investigate resistance to potential drugs for advanced prostate cancer.
> In March 2017, Roche Diagnostics (Switzerland), launched AVENIO circulating tumor DNA (ctDNA) Analysis Kits. The kits include all reagents, bioinformatics and software to make ctDNA testing accessible to all NGS laboratories.
> In April 2017, Myriad Genetics Inc. (US), partnered with BeiGene (Cayman Islands). BeiGene is a biopharmaceutical company focused on developing molecularly targeted and immuno-oncology drug candidates for the treatment of cancer. As per this partnership, BeiGene will use Myriad’s myChoice HRD and BRACAnalysis CDx companion diagnostic tests to support the clinical development of its novel PARP inhibitor, BGB-290.
> In April 2017, Menarini Silicon Biosystems (Italy), Inc. acquired Janssen Diagnostics, LLC. (US). This acquisition of Janssen Diagnostics' business related to CELLSEARCH Circulating Tumor Cell System. The acquisition marks Menarini-Silicon Biosystems’ first entry into the US diagnostics market.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
sales@marketsandmarkets.com

AI in Genomics Market Growth By Offering, Functionality, Application and Region

According to the new market research report AI in Genomics Market is projected to reach USD 1,671 million by 2025 from USD 202 million in 2020, at a CAGR of 52.7% between 2020 and 2025

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=36649899

The need to control drug development and discovery costs and time, increasing public and private investments in AI in genomics, and the adoption of AI solutions in precision medicine are driving the growth of this market. However, the lack of a skilled AI workforce and ambiguous regulatory guidelines for medical software are expected to restrain the market growth during the forecast period.

Based on offering, the Artificial Intelligence In Genomics Market is segmented into software and services. The software and services segment accounted for largest share of the global AI in genomics market in 2019. Software is needed to generate new insights from large-scale datasets and help understand genomic variations, thus enhancing the search for disease-causing variants and reducing clinical analysis times. The benefits offered by AI in software are driving its adoption among end users.

Based on functionality, the AI in genomics market is segmented into genome sequencing, gene editing, clinical workflows, and predictive genetic testing & preventive medicine. Genome sequencing was the largest functionality segment in this market in 2019 and is estimated to grow at highest CAGR in coming years. The large share of this segment can be attributed to the use of AI solutions to identify chromosomal disorders, dysmorphic syndromes, teratogenic disorders, and single-gene disorders.

In 2019, North America accounted for the largest share of the AI in genomics market, followed by Europe. The large share of North America can be attributed to the increasing research funding and government initiatives for promoting precision medicine in the US.

Request For Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=36649899

Prominent players in the market are IBM (US), Microsoft (US), NVIDIA Corporation (US), Deep Genomics (Canada), BenevolentAI (UK), Fabric Genomics Inc. (US), Verge Genomics (US), Freenome Holdings, Inc. (US), MolecularMatch Inc. (US), Cambridge Cancer Genomics (UK), SOPHiA GENETICS (US), Data4Cure Inc. (US), PrecisionLife Ltd (UK),Genoox Ltd. (US), Lifebit (UK), Diploid (Belgium), FDNA Inc. (US), DNAnexus Inc. (US), Empiric Logic (Ireland), Engine Biosciences Pte. Ltd. (US)

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com

Lab Informatics Market Insights on Scope and Growing Demands 2024

 

According to research report the Lab Informatics Market is estimated to reach USD 3.8 billion by 2024 from USD 2.6 billion in 2019, at a CAGR of 7.5% during the forecast period.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=203037633

The increasing need for laboratory automation; the development of integrated lab informatics solutions; the need to comply with regulatory requirements; and the growing demand in biobanks/biorepositories, academic research institutes, and CROs are the major factors driving the growth of the laboratory informatics market. On the other hand, lack of integration standards and high maintenance and services cost are expected to restrain the growth of this market in the coming years.

The services segment accounted for the largest share of the market in 2018.

Based on components, the Lab Informatics Market is segmented into services and software. The services segment dominated this market in 2018. The large share of the services segment can be attributed to the growing technological advancements in solution offerings by various vendors, increasing adoption of cloud-based solutions, growing need for consulting services, and the recurring nature of services. Furthermore, in terms of IT usage and skill, the life science industry relies heavily on service providers.

The cloud-based models segment is expected to grow at the highest CAGR during the forecast period.

On the basis of deployment model, the laboratory informatics market is segmented into on-premise, cloud-based, and remotely hosted models. The cloud-based models segment is expected to grow at the highest CAGR during the forecast period. Factors such as on-demand self-serving analytics, no upfront capital investment for hardware, extreme capacity flexibility, and a pay-as-you-go pricing model will boost the demand for cloud-based laboratory informatics solutions in the coming years. However, data transfer complexities and data security concerns may hinder the growth of this market segment.

The laboratory informatics market is diversified and highly competitive, with a large number of players competing for market space. The prominent players in the market are Thermo Fisher Scientific Inc. (US), LabVantage Solutions, Inc. (US), LabWare (US), Abbott Informatics (US), LabLynx, Inc. (US), Waters (US), Agilent Technologies, Inc. (US), Autoscribe Informatics (US), Dassault Systèmes (Paris, France), LABWORKS LLC (US), KineMatik (Ireland), Accelerated Technology Laboratories (ATL) (US), and PerkinElmer Inc. (US).

Recent Developments

> In August 2018, Waters (US) signed an agreement with Restek Corporation (US). Under this agreement, Waters and Restek Corporation agreed to provide training and application support of GC-MS methods and workflows for pesticide monitoring and screening to food safety laboratories.
> In May 2018, Agilent Technologies (US) acquired Genohm (Switzerland). This acquisition enhanced Agilent’s current software portfolio by adding LIMS and workflow management, thus expanding the company’s ELN capabilities.
> In February 2018, Autoscribe Informatics opened a new operation facility in Australia to expand its LIMS customer base to Australia and New Zealand.
> In March 2017, Thermo Fisher Scientific acquired Core Informatics. This acquisition enhanced Thermo Fisher’s existing informatics solutions and its cloud platform, including its laboratory information management systems (LIMS), electronic laboratory notebook (ELN) technologies, and scientific data management solutions (SDMS).

Request For Report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=203037633

Geographically, the Lab Informatics Market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). In 2018, North America dominated the market, followed by Europe. Growth in the North American market is supported by the growing demand for the integration of laboratory systems, rising government funding for research, growth in biobanks, need for early drug discovery, easy availability of laboratory informatics products and services, and stringent regulatory requirements across industries.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
sales@marketsandmarkets.com

In Vitro Toxicology Testing Market Insights on Scope and Growing Demands 2025

According to the new market research report In Vitro Toxicology Testing Market is expected to reach USD 14.9 billion by 2025 from an estimated USD 9.1 billion in 2020, at a CAGR of 10.3%.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=209577065

The major factors driving the growth of this in vitro toxicity testing market are the opposition to animal testing, technological advancements, and increasing R&D expenditure to detect toxicity at an early stage during drug development are the primary growth drivers for this market.

By product and service, the consumables segment is expected to account for the largest share of the in vitro toxicology testing market

The consumables segment is estimated to account for the largest market share in 2019. The large share of this segment can be attributed to the increasing demand for high-quality reagents and the repeated use of media and reagents in in vitro toxicology studies.

In the toxicity endpoints and tests market, the organ toxicity segment is expected to grow at the highest CAGR during the forecast period

The organ toxicity segment is expected to grow at the highest CAGR during the forecast period. The growth in this segment can be attributed to factors such as the increasing focus on drug safety and consumer-product safety, along with the need to screen potential drug targets during the early stage of drug development.

Based on the technologies used in the in vitro toxicology testing, the cell culture technologies segment is expected to account for the largest share of the in vitro toxicology testing market

The cell culture technologies segment is estimated to account for the largest market share in 2018. The large share of this segment can be attributed to the fact that it is the most preferred technique for toxicity testing, being capable of mimicking in vivo conditions.

Asia Pacific is estimated to be the fastest-growing market for in vitro toxicology testing during the forecast period

The APAC in vitro toxicology testing market is projected to register the highest growth during the forecast period. Factors such as emergence of CROs for outsourcing toxicology-related research projects, opposition to animal testing resulting in the use of alternate methods, increasing pharmaceutical drug pipeline, and growing consumer awareness of product safety are some of the key factors driving the growth of the market in the APAC.

Request For Report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=209577065

The prominent players in the in vitro toxicology testing market include Thermo Fisher Scientific Inc. (US), Covance (US), Bio-Rad Laboratories, Inc. (US), GE Healthcare (US), SGS S.A. (Switzerland), QIAGEN N.V. (Germany), Promega Corporation (US), Eurofins Scientific SE (Luxembourg), Merck KGaA (Germany), Charles River Laboratories International, Inc. (US), Catalent, Inc. (US), Cyprotex (UK), Gentronix Limited (UK), BioIVT (US), and MB Research Laboratories (US).

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
sales@marketsandmarkets.com

Clinical Microbiology Market Insights on Scope and Growing Demands 2025

According to the new market research report Clinical Microbiology Market is estimated to be USD 3.9 billion in 2020 and projected to reach USD 5.3 billion by 2025, at a CAGR of 6.5%.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=219135367

The global microbiological testing market offers significant growth potential for prominent as well as emerging product manufacturers. Technological advancements, increased funding and public-private investments and rising incidence of infectious diseases and growing outbreak of epidemics (such as COVID-19) are some of the key factors driving the growth of the microbiological testing/clinical microbiology market.

Demand for conventional laboratories result in the segment occupying the high share of the Microbiology Testing Market

The product segment owns a good market share In the clinical microbiology market. The large share of this segment is attributed to factors such as the significant adoption of conventional laboratory instruments among researchers and academia (coupled with growing industry-academia collaborations for genomic research), technological advancements in the field of molecular techniques and proteomics (such as the integration of microfluidics with PCR and nanotechnology with qPCR techniques), and the ongoing trend of laboratory automation among clinical laboratories.

BioMérieux (France), Danaher Corporation (US), Becton, Dickinson and Company (US), Abbott Laboratories (US), and Roche Diagnostics (Switzerland). Other prominent players include Thermo Fisher Scientific (US), QIAGEN (Netherlands), 3M (US), Bio-Rad Laboratories (US), Bruker Corporation (US), and Hologic (US).

These suppliers have their manufacturing facilities spread across regions such as North America and Europe. COVID-19 has impacted their businesses as well. Demand for clinical microbiology from key end-users has declined a bit amidst the global COVID-19 pandemic. Industry experts believe that COVID-19 will have a short-term decline in the growth for the clinical microbiology market in 2020, but will experience normal development as the market gradually steadies by the end of 2020.

Recent Developments

> In 2019, bioMérieux (France) acquired Invisible Sentinel (US), a company engaged in the development, manufacturing, and marking of molecular diagnostic tools for the rapid, accurate, and reliable detection of pathogens and spoilage organisms in food and beverages
> In 2018, bioMérieux (France) acquired Astute Medical (US), a manufacturer of immunoassays and protein biomarkers for high-risk medical conditions and disease identification and validation. This helped bioMérieux to expand its portfolio of immunoassays.
> In 2018, Beckman Coulter (US) and NTE-SENER (Spain) partnered to launch the DxM 6100 Autoplak Advanced System in Europe.
> In 2017, Abbott (US) acquired Alere (US), a leading company in diagnostics and point-of-care testing. This acquisition helped the company expand its product portfolio and strengthen its market position in the clinical microbiology testing market.

Reagent estimated to be the growing market

The clinical microbiology reagents market is expected to witness sustained demand during the forecast period, owing to the high prevalence of infectious diseases across major markets (resulting in a growing number of clinical diagnostic procedures), the increasing trend of reagent rental agreements along with instrument sales, and a growing number of life science researches in the field of specific reagents for targeted infectious disease diagnosis and treatment, especially across emerging countries. However, growing laboratory automation has reduced overall reagent consumption in recent years, which is expected to affect the sales of reagents overall.

Request For Report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=219135367

Asia Pacific likely to emerge as the fastest-growing clinical microbiology market, globally

Geographically, the emerging Asian countries, such as China, India, South Korea, Taiwan, and Singapore, are offering high-growth opportunities for market players. The Asia Pacific clinical microbiology market is projected to grow at the highest CAGR from 2020 to 2025. Government efforts to increase awareness related to genome-based infectious disease diagnosis; supportive regulations for the development and commercialization of advanced clinical microbiology products; rising healthcare expenditure; the increasing number of hospitals and clinical diagnostic laboratories in India and China; expanding research base across India, China, and Japan; and the rising incidence of infectious diseases are driving the growth of the APAC Microbiology Testing Market.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
sales@marketsandmarkets.com

Healthcare IT Integration Market Insights on Scope and Growing Demands 2025

According to the new market research report Healthcare IT Integration Market is projected to reach USD 6.0 billion by 2025 from USD 3.5 billion in 2020, at a CAGR of 11.4% during the forecast period.

The increasing need for integration primarily drives the market for healthcare IT integration solutions as a result of the rising healthcare costs and the growing volume of data generated in healthcare systems. The need to improve patient safety and favorable government and private support for HCIT will also contribute to market growth in the coming years. However, the high cost of HCIT integration is limiting the overall adoption of these solutions.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=228536178

By end user, the hospital segment is expected to grow at the highest CAGR during the forecast period.

Based on end-user, the Healthcare IT Integration Solutions Market is segmented into hospitals, laboratories, clinics, diagnostic imaging centers, and other end users. Hospitals are expected to grow at the highest CAGR during the forecast period. This growth can be attributed to the high purchasing power of hospitals to buy advanced healthcare IT integration solutions and the increasing focus on offering high-quality patient care through the use of HCIT solutions.

The services segment is expected to for the largest share of the Healthcare IT Integration Market in 2019.

Based on product & service, the market is categorized mainly into products and services. In 2019, the services segment was expected to account for the largest share of the Healthcare IT Integration Solutions Market. The large share of this segment can primarily be attributed to its indispensable nature. In addition to this, the rising need for simplifying workflows in healthcare organizations; the increasing demand for data standardization; and the growing need to build, design, and implement standardized, interoperable networking platforms are also driving the demand for healthcare IT integration services.

North America to hold the largest regional Healthcare Integration Market share in 2019.

North America is expected to account for the largest share of the Healthcare Integration Market in 2019, followed by Europe. The large share of North America can be attributed to the high adoption of healthcare IT technologies, initiatives undertaken by the US Federal government towards improving patient care and reducing healthcare costs, and the growing need for the optimization of healthcare infrastructure. In addition, factor such as the widespread adoption of clinical device connectivity and interoperability solutions to curtail the rising healthcare costs, rising number of coronavirus (COVID-19) patients in the US, and stringent regulations and guidelines laid down by the various government and non-government authorities such as the Health Insurance Portability and Accountability Act (HIPPA), the Federal Communications Commission (FCC), and the Centers for Medicare and Medicaid Services (CMS) are further driving the growth of the Healthcare IT Integration Solutions Market in North America.

Request For Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=228536178

The leading players in this Healthcare IT Integration Market include Infor (US), InterSystems Corporation (US), Cerner Corporation (US), Allscripts Healthcare Solutions, Inc. (US), Koninklijke Philips (Netherlands), Capsule Technologies Inc. (US), AVI-SPL, Inc. (US), GE Healthcare (US), Oracle Corporation (US), IBM (US), Corepoint Health (Lyniate) (US), Orion Health (New Zealand), NextGen Healthcare Inc. (US), iNTERFACEWARE, Inc. (Canada), Epic Systems Corporation (US) and MEDITECH (US).

Recent Developments

> In February 2020, Rhapsody and Corepoint launched their combined entity known as Lyniate, which supports both Rhapsody and Corepoint product lines and customer base.
> In July 2019, Corepoint Health launched Corepoint One Interoperability Solution, a cloud-based integration engine.
> In April 2019, GE Healthcare collaborated with the American College of Radiology (ACR) (US) to integrate its Edison platform with ACR’s Artificial Intelligence-Lab.
> In February 2019, Veradigm (US) (a part of Allscripts Healthcare) entered into a partnership with NextGen Healthcare, Inc. (US) to improve connectivity and data exchange with payers and labs.
> In August 2018, InterSystems Corporation (US) collaborated with Greater Houston Healthconnect (US) to offer Health Information Exchange (HIE) services to improve quality, patient safety, and efficiency of care.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com

Ambulatory EHR Market Insights on Scope and Growing Demands 2025

According to the new market research report Ambulatory EHR Market is expected to reach USD 6.8 billion by 2025 from USD 5.2 billion in 2020, at a CAGR of 5.7% during the forecast period of 2020 to 2025.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=235617627

The key factors propelling the growth of the global ambulatory EHR market are government support for the adoption of HCIT, an increase in the COVID-19 patient volume, growing usage of EHR solutions, and the need to curtail healthcare costs. On the other hand, heavy infrastructure investments and the high cost of deployment are limiting the growth of the global market to a certain extent.

The leading players in this market include Epic Systems Corporation (US), Cerner Corporation (US), Allscripts Healthcare Solutions (US), Medical Information Technology, Inc. (MEDITECH, US), CPSI (US), NextGen Healthcare Information Systems, LLC (US), eClinicalWorks (US), athenahealth, Inc. (US), Modernizing Medicine, Inc. (US), Medical Transcription Billing Corporation (MTBC, US), Amazing Charts, LLC (US), Greenway Health (US), eMDs, Inc. (US), NetSmart Technologies (US), and CureMD (US).

The cloud-based solutions segment is projected to occupy the majority of the market share during the forecast period.

Based on delivery mode, the hospital EHR market is segmented into on-premise and cloud-based solutions. In 2019, the cloud-based solutions segment accounted for the largest share of the market. The market is mainly driven by the advantages associated with cloud-based solutions, which include flexibility and cost reductions in healthcare delivery.

Practice management application is the largest application segment in the market

On the basis of application, the global market has been segmented into practice management, patient management, e-prescribing, referral management, population health management, decision support, and health analytics. The practice management segment commanded the largest share of the global ambulatory EHR market in 2019. The significant share of this application segment can primarily be attributed to the wide range of advantages associated with practice management solutions, including increased efficiency of day-to-day operations, enhanced value of services provided to patients, and improved adherence to compliance requirements.

Request For Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=235617627

In 2019, North America accounted for the largest share of the market.

The ambulatory EHR market is predominantly divided into five major geographies, namely, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America accounted for the largest share of this market, followed by North America. Growth in the North American market can be attributed to factors such as federal mandates, the increasing geriatric population, collaboration between stakeholders, the need to curtail healthcare costs, payment deductions driving the adoption of EHR, conferences and workshops to raise awareness in the US, growing efforts to enhance healthcare delivery, and the adoption of digital recordkeeping in Canada.

Recent Developments

> In January 2020, MTBC (US) acquired CareCloud Corporation (US) that helped MTBC yield greater operating efficiencies, accelerate growth, and provide more flexibility for future expansion.
> In April 2020, MEDITECH (US) collaborated with MedPower, LLC (US) to provide online training programs to aid the process of onboarding of hospitals that are using MEDITECH’s EHR solutions, amidst the COVID-19 pandemic.
> In October 2019, Allscripts Healthcare Solutions (US) signed an agreement with Northwell Health (US) to jointly develop a next-generation, AI-powered electronic health record.
> In January 2020, NextGen Healthcare (US) partnered with Doctible(US) to integrate the Doctible platform with NextGen Office, a cloud-based EHR solution, that will help healthcare providers automate back-office tasks and receive real-time feedback from patients.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com

Pacemakers Market worth $5.3 billion by 2027

According to a new market research report Pacemakers Market by Implantability (External), Technology (Single Chamber, Dual Chamber, CRT-P/Biventricular Pacemaker), Type (Conventional, MRI Compatible), End Users (Hospitals and Cardiac Centers, Ambulatory Surgery Center) - Global Forecast to 2027, is projected to reach USD 5.3 billion by 2023 from USD 4.5 billion in 2019, at a CAGR of 2.0%. Growth in this market is driven by increasing prevalence of cardiovascular diseases and technological advancements in devices.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=243344814

Browse and in-depth TOC on "Pacemakers Market"

114 - Tables

24- Figures

122 - Pages

The implantable pacemakers segment, by implantability, projected to occupy the majority of the market share and grow at the fastest rate during the forecast period.

The implantable pacemakers segment is projected to be the fastest-growing segment, by implantability, during the forecast period. The large share of the implantable pacemakers segment is primarily attributed to the increasing prevalence of CVDs and the rising preference for these pacemakers due to their benefits over their external counterparts.

The MRI compatible pacemakers segment, by livestock, is projected to occupy the majority of the market share and grow at the fastest rate during the forecast period.

The MRI compatible pacemakers segment is projected to be the fastest-growing segment, by type, during the forecast period. This can be attributed to the growing number of patients with implanted pacemakers and the increasing need for MRI scans in the geriatric population, as patients in this age group are more likely to have cardiac devices such as pacemakers.

North America is projected to account for the largest market size in the pacemakers market during the forecast period.

North America is estimated to account for the largest share of the market. Factors such as the rising prevalence of CVDs, growing geriatric population, increasing healthcare expenditure, and the availability of technologically advanced devices are driving the growth of the pacemakers market in North America.

Request For Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=243344814

Major vendors in the pacemakers market include Medtronic (Ireland), Abbott (US), and Boston Scientific (US), BIOTRONIK (Germany), LivaNova (UK), OSCOR (US), Pacetronix (India), MEDICO (Italy), Osypka Medical (Germany), and Lepu Medical (China).

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Content Source: https://www.marketsandmarkets.com/PressReleases/pacemaker.asp

Biopsy Devices Market Worth 2.42 Billion USD by 2022

According to a new market research report Biopsy Devices Market by Product (Core Needle Biopsy, Aspiration Biopsy, Vacuum Assisted Biopsy) Application (Breast Biopsy, Lung Biopsy, Prostate Biopsy) Guidance (Stereotactic, Ultrasound) & by End User (Hospital) - Global Forecast to 2022, published by MarketsandMarkets™, the market is expected to reach USD 2.42 Billion by 2022 from an estimated USD 1.74 Billion in 2017, at a CAGR of 6.8% during the forecast period.

Browse 180 Market Data Tables and 42 Figures spread through 219 Pages and in-depth TOC on "Biopsy Devices Market"

Download PDF Brochure: http://www.marketsandmarkets.com/pdfdownload.asp?id=132886515

The Report analyzes and studies the major market drivers, restraints, and opportunities in North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.

Factors such as rising prevalence of cancer, increasing preference for minimally invasive surgeries, and initiatives undertaken by governments & global health organizations are the major factors driving the growth of this market.

By product, the needle-based biopsy instruments segment accounted for the largest share of the market

On the basis of product, the needle-based biopsy instruments segment accounted for the largest share of the global biopsy devices market in 2016. This can be attributed to the preference of needle-based biopsies over open surgical biopsies and increasing preference for minimally invasive surgeries.

The lung biopsy segment is expected to highest growth during the forecast period

Based on application, the lung biopsy segment accounted for the largest share of the biopsy devices market. The growing prevalence of lung cancer will drive market growth. Additionally, the availability of funding for lung cancer research is contributing to the growth of this market segment.

The ultrasound-guided biopsy segment dominated the market in 2016

Based on guidance technique, the ultrasound-guided biopsy segment accounted for the largest share of the biopsy devices market. This quick and simple procedure offers advantages, such as no ionizing radiation exposure, low complication rate, and lower cost as compared to other biopsy techniques.

The hospitals segment held the highest CAGR during the forecast period

Based on end user, the hospitals segment is expected to register the highest growth rate during the forecast period. The strong financial capabilities of hospitals and the presence of trained professionals are the major factors supporting the rising adoption of biopsy devices among hospitals.

North America dominated the market in 2016

North America accounted for the largest share of the biopsy devices market in 2016, followed by Europe. The rising prevalence of cancer, government initiatives to spread awareness about cancer, favorable reimbursement scenario for biopsy devices in the U.S., and the presence of key players in the region are the key factors driving the growth of the biopsy devices market in North America.

Request For Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=132886515

The major players in the biopsy devices market are C. R. Bard, Inc. (U.S.), Becton, Dickinson and Company (U.S.), Cook Group Incorporated (U.S.), Devicor Medical Products, Inc., (Leica Biosystems) (Germany), Argon Medical Devices (U.S.), B. Braun Melsungen AG (Germany), Cardinal Health, Inc. (U.S.), Olympus Corporation (Japan), Boston Scientific Corporation (U.S.), FUJIFILM Holdings Corporation (Japan), INRAD, Inc. (U.S.), and Medtronic plc (Ireland).

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the “Growth Engagement Model – GEM”. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write “Attack, avoid and defend” strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, “Knowledge Store” connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Content Source: https://www.marketsandmarkets.com/PressReleases/biopsy-device.asp 

Medical Device Contract Manufacturing Market worth $113.3 billion by 2026

According to the new market research report Medical Device Contract Manufacturing Market by Device Type (IVD (Equipment, Consumable), Cardiovascular, Diabetes Care, Drug Delivery, Orthopedic, Ophthalmic, Endoscopy Devices), Class of Device (Class I, II, III), & Services - Global Forecast to 2026, published by MarketsandMarkets™, the global market is estimated to reach USD 113.3 billion in 2026 from USD 65.9 billion in 2021, at a CAGR of 11.5% during the forecast period.

Browse in-depth TOC on “Medical Device Contract Manufacturing Market”

292 – Tables
59 – Figures
361 – Pages

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=170622851

The key factors driving the growth of the medical device contract manufacturing market include the overall growth of the medical devices market, mainly due to rising disease prevalence, life expectancy, and the geriatric population. Technological advancement has prompted end users to overhaul or update their manufacturing systems. As this is a costly process, they look to contract manufacturing. In addition to this, the COVID-19 outbreak has accelerated the adoption of advanced diagnostics and patient care devices for better treatment management.

However, market growth is impeded by the growing consolidation in the medical devices market. Larger players, to develop their manufacturing capabilities to save costs, focus on the acquisition of smaller players and CMOs themselves. This may affect the overall pace of market growth.

The IVD devices segment accounted for the largest share of medical device contract manufacturing market in 2020

Based on device type, the market is broadly segmented into IVD devices, diagnostic imaging devices, cardiovascular devices, drug delivery devices, orthopedic devices, respiratory care devices, ophthalmology devices, surgical devices, diabetes care devices, dental devices, endoscopy devices, gynecology/urology devices, personal care devices, neurology devices, and other devices. In 2020, IVD devices accounted for the largest share of the market. The large share of this segment can be attributed to the increasing volume of IVD tests performed globally, the COVID-19 pandemic, the increasing availability of IVD kits and reagents, the growing number of hospitals & clinical laboratories in developing countries, automation & technological advancements in instruments with high-throughput capabilities, and advances in life sciences research.

Class II medical devices segment accounted for the largest share of the medical device contract manufacturing market in 2020.

Based on the class of device, the market is segmented into Class I, Class II, and Class III medical devices. In 2020, the Class II medical devices segment is projected to grow at the highest CAGR in the market. The growth of this segment can be attributed to the large number of medical devices that fall under this device class and their greater utilization (compared to other classes) by end users and caregivers in the healthcare industry. In addition, due to the outbreak of COVID-19, governments minimized the regulatory compliance on these devices and issued Emergency Use Authorizations (EUA) for diagnostics and PPE kits, thereby boosting the market growth.

In 2020, the device development and manufacturing services segment accounted for the largest share of the market

Based on service, the medical device contract manufacturing market is segmented into device development and manufacturing services, quality management services, packaging and assembly services and other services. The device development and manufacturing services segment dominated this market. The increasing adoption of contract manufacturing services in the medical device industry, growth in the medical devices market (especially in the single-use disposable medical devices market), and improving device development and manufacturing capabilities are the major factors responsible for the large share of this segment.

Asia Pacific is expected to witness the fastest growth during the forecast period of 2021–2026.

Geographically, the medical device contract manufacturing market has been segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific is expected to witness the fastest growth during the forecast period. The dominant share of the APAC region is mainly attributed to the lower cost of raw materials & labor compared to the developed countries, the increasing demand for medical devices due to improving healthcare infrastructure, the adoption of technologically advanced products, and the presence of a less stringent regulatory than most developed countries.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=170622851

The prominent players in this market are Flex, Ltd. (Singapore), Jabil, Inc. (US), TE Connectivity, Ltd. (Switzerland), Sanmina Corporation (US), Nipro Corporation (Japan), Celestica International (Canada), Plexus Corporation (US), Benchmark Electronics, Inc. (US), Integer Holdings Corporation (US), Gerresheimer Ag (Germany), West Pharmaceutical Services, Inc. (US), Nortech Systems, Inc. (US), Consort Medical PLC (UK), Kimball Electronics Inc. (US), and Teleflex Incorporated (US), Tecomet, Inc. (US), SMC Ltd. (US), Nemera (France), and Tessy Plastics Corporation (US), among others.

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the “Growth Engagement Model - GEM”. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write “Attack, avoid and defend” strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, “Knowledge Store” connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Content Source: https://www.marketsandmarkets.com/PressReleases/medical-device-contract-manufacturing.asp

Contrast Media Market worth $5.9 billion by 2026

According to the new market research report Contrast Media Market by Type (Iodinated Contrast Media), Modality (X-Ray/CT, MRI, and Ultrasound), Application (Radiology), End User (Hospitals), Indication (Cancer), Route of Administration (Oral), Region - Global Forecast to 2026, published by MarketsandMarkets™, the global Contrast Media Market is projected to USD 5.9 billion by 2026 from USD 4.9 billion in 2021, at a CAGR of 3.7% during the forecast period.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=911

The Rising prevalence of chronic diseases, growing approvals of contrast agents, rising volume of CT and MRI examinations performed, growing number of diagnostic centers and hospitals, and availability of reimbursement are the major factors driving the growth of the contrast agents market.

The microbubble contrast media segment is expected to grow at the highest CAGR during the forecast period and iodinated contrast media accounted for the largest share in 2020.

Based on type, the contrast media market is segmented into iodinated contrast media, gadolinium-based contrast media, microbubble contrast media, and barum-based contrast media. Iodinated contrast media account for the largest share of the market. The large share of this segment can be attributed to the growing number of angioplasty procedures performed globally.

North America was the largest regional market for the contrast agents market in 2020

The contrast media market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latin America and the Middle East & Africa (MEA). North America was the largest regional market in 2020. The large share of the North American market can be attributed to presence of major players in the region, high prevalence of chronic disorders, growing geriatric population, and the increasing adoption of minimally invasive procedures.

However, the Asia Pacific contrast media market is estimated to grow at the highest CAGR during the forecast period. The rising prevalence of chronic diseases, the growing demand for quality medical care, increasing healthcare spending and government initiatives, rising disposable income, growth in the medical device industries, and improvements in healthcare infrastructure in Southeast Asian countries are the major factors driving the growth of the market in the Asia Pacific.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=911

The global contrast media market is consolidated. The prominent players operating in this market include GE Healthcare (US), Bracco Imaging SPA (Italy), Bayer AG (Germany), Guerbet (France), J.B. Chemicals and Pharmaceuticals Ltd. (India), Lantheus Medical Imaging, Inc. (US), Unijules Life Sciences Ltd. (India), and SANOCHEMIA Pharmazeutika GmbH (Austria).

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the “Growth Engagement Model – GEM”. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write “Attack, avoid and defend” strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, “Knowledge Store” connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Content Source: https://www.marketsandmarkets.com/PressReleases/contrast-media.asp

Defibrillators Market Worth $11.7 Billion by 2025

According to the new market research report Defibrillators Market by Product [Implantable Cardioverter Defibrillator (Transvenous ICD, Single & Dual Chamber, CRT-D, S-ICD), External (Manual, AED, Wearable)], End User (Hospitals, Pre-hospital, Public Access, Home care) - Global Forecast to 2025, published by MarketsandMarkets™, the Defibrillators Market is projected to reach USD 11.7 billion by 2025 from USD 9.6 billion in 2019, growing at a CAGR of 3.4% during the forecast period.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=549

The growth in this market is driven by the rising prevalence of target diseases, growing focus on providing public-access defibrillators, and training and awareness programs on defibrillators. In addition, emerging markets and the development of S-ICDs and MRI-compatible ICDs and CRT-Ds are expected to offer growth opportunities for players in the market. However, issues related to the use of implantable and automated external defibrillators, frequent product recalls, and a lack of awareness about sudden cardiac arrest in developing nations are expected to hinder the growth of the market during the forecast period.

Browse in-depth TOC on "Defibrillators Market"

132 – Tables
30 – Figures
158 – Pages

The ICDs segment accounted for the largest share of the market in 2019

On the basis of type, the market is segmented into implantable cardioverter defibrillators (ICDs) and external defibrillators. The ICDs market is further segmented into transvenous implantable cardioverter defibrillators (T-ICDs) and subcutaneous implantable cardioverter defibrillators (S-ICDs). The T-ICDs segment is further categorized as single-chamber ICDs, dual-chamber ICDs, and cardiac resynchronization therapy defibrillators (CRT-Ds). The External Defibrillators Market is further segmented into manual and semi-automated external defibrillators, fully automated external defibrillators, and wearable cardioverter defibrillators (WCDs).

The ICDs segment accounted for the largest share of the market in 2019. Factors such as the development of technologically advanced devices with extended longevity, rapid growth in the number of implant procedures, and increasing adoption of cardiac resynchronization therapy defibrillators (CRT-Ds) and S-ICD systems across the globe are contributing to the large share of this segment.

The hospitals, clinics, and cardiac centers segment accounted for the largest share of the global Defibrillators Market in 2019

On the basis of end users, the market is segmented into hospitals, clinics, and cardiac centers; prehospital care settings; public access markets; alternate care facilities; and home care settings. The hospitals, clinics, and cardiac centers segment accounted for the largest share of the global market in 2019. The growing number of cardiac implant procedures and the availability of reimbursements across developed markets are the major factors driving the growth of this end-user segment.

In 2019, North America accounted for the largest share of the Defibrillators Market

In 2019, North America accounted for the largest share of the market. The rising geriatric population, increasing incidence of cardiac diseases, and technological advancements are the major factors driving the growth of the market in North America. Increasing efforts by governments to provide the necessary care to cardiac arrest victims at public places through public-access defibrillation programs have also increased the demand for defibrillators in the region.

Request For Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=549

Prominent players in the Defibrillators Market include Medtronic (Ireland), St. Jude Medical (US), Boston Scientific (US), Koninklijke Philips N.V. (Netherlands), ZOLL Medical (US), BIOTRONIK (Germany), Physio-Control (US), Nihon Kohden (Japan), SCHILLER AG (Switzerland), Mindray Medical (China), Mediana (South Korea), and METsis Medikal (Turkey).

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Content Source: https://www.marketsandmarkets.com/PressReleases/automated-external-defibrillator.asp

Oral Care Market Worth 53.3 Billion by 2025

According to the new market research report Oral Care Market by Product (Toothbrush (Manual, Electric, Battery), Toothpaste (Pastes, Gels, Powder, Polish), Breath Freshener, Rinse & Distribution Channel (Consumer Stores, Retail Pharmacy, E-Commerce), and Region- Global Forecast to 2025, published by MarketsandMarkets™, the Oral Care Market is projected to reach USD 53.3 billion by 2025 from USD 45.8 billion in 2020, at a CAGR of 3.1%.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=80546246

The Factors such as the rising awareness about oral hygiene, growing incidence of dental diseases, and technological advancements in oral care products are expected to drive the growth of the Oral Care Market. Increasing the online purchase of oral care products is expected to create new growth opportunities for players operating in this market.

The toothpaste segment is expected to account for the largest share of the Oral Hygiene Market in 2019.

Based on product, the market is categorized into toothpaste, toothbrushes & accessories, mouthwashes/rinses, denture products, dental accessories/ancillaries, and dental prosthesis cleaning solutions. In 2019, the toothpaste segment was expected to account for the largest share of the Oral Care Market. The large share of this segment can primarily be attributed to the enormous adoption of toothpaste for maintaining oral hygiene, the treatment of dental caries, and its use in post-surgical procedures.

Browse in-depth TOC on “Oral Hygiene Market”
367 – Tables
47 – Figures
336 – Pages

By distribution channel, the online distribution segment is expected to grow at the fastest CAGR in the forecast period

By distribution channel, the Oral Hygiene Market is segmented into consumer stores, retail pharmacies, dental dispensaries, and online distribution. Online distribution is expected to grow at the fastest CAGR in the forecast period in this segment. This high growth can be attributed to the increase in the number of e-commerce platforms focused on oral care/oral hygiene products, better convenience and availability of a variety of products through this channel along with proper discounts.

The Asia Pacific is expected to dominate the market in 2019 as well as serves higher growth potential during the forecast period.

In 2019, the Asia Pacific was estimated to account for the largest share of the Oral Care Market, followed by Europe. The dominant share of the Asia Pacific is attributed mainly to the rising geriatric population, growing prevalence of dental diseases, increasing focus of prominent players on emerging Asian countries, increasing healthcare expenditure (coupled with the increasing disposable income), raising awareness on oral healthcare, and the willingness to spend more on dental care. Other factors, such as the growing number of dental professionals, along with the increasing number of dental visits, will further support the growth of the Oral Hygiene Market in this regional segment during the forecast period.

Request For Report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=80546246

The key players operating in the Oral Care Product Market include Colgate-Palmolive Company (US), The Procter & Gamble Company (US), GlaxoSmithKline PLC (UK), Unilever PLC (UK), Koninklijke Philips N.V. (Netherlands), Johnson & Johnson (US), GC Corporation (Japan), 3M Company (US), Lion Corporation (Japan), Church & Dwight Co., Inc. (US), Sunstar Suisse S.A. (Switzerland).

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth

markets following the “Growth Engagement Model – GEM”. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write “Attack, avoid and defend” strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, “Knowledge Store” connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Content Source: https://www.marketsandmarkets.com/PressReleases/oral-care.asp

ECMO Machine Market Worth 305.3 Million USD by 2021 - Exclusive Report by MarketsandMarkets™

According to a new market research report "EMO Machine Market by Modality (Veno-Arterial (VA), Veno-Venous (VV), Arterio-Venous (AV)), Application (Respiratory, Cardiac, Extracorporeal Cardiopulmonary Resuscitation (ECPR)), and Region - Analysis & Forecasts to 2021" published by MarketsandMarkets, The market is expected to reach USD 305.3 Million by 2021 from USD 247.2 Million in 2016, at a CAGR of 4.3%.

Browse 78 market data Tables and 31 Figures spread through 129 Pages and in-depth TOC on "Extracorporeal Membrane Oxygenation Machine Market"

Download PDF Brochure: http://www.marketsandmarkets.com/pdfdownload.asp?id=255167654

The report analyzes and studies the major market drivers, restraints/challenges, and opportunities for the forecast period of 2016 to 2021. A number of factors such as the growing cardiovascular and respiratory diseases, rising adoption of ECMO as a bridge to heart & lung transplantation, growing number of ECMO centers, conferences and training programs to increase awareness, and technological advancements are the significant factors driving the growth of this Extracorporeal Membrane Oxygenation Machine Market. In addition, the growing aging population and the number of people suffering from cardiopulmonary diseases in populous countries such as India and China are factors that are expected to offer significant growth opportunities for ECMO systems. However, complications associated with ECMO such as bleeding, infections, and technical failures; along with high cost and lack of skilled professionals is a challenge to the market.

The global ECMO machine market is segmented on the basis of modality, applications, and regions. Based on the modality, the global market is segmented into venoarterial (VA), venovenous (VV), and arteriovenous (AV). The venovenous (VV) segment is estimated to account for the largest share of the global market in 2016, and venoarterial (VA) segment is projected to grow at the highest CAGR in the forecast period.

Based on application, the global Extracorporeal Membrane Oxygenation Machine Market is segmented into Respiratory, Cardiac, and Extracorporeal Cardiopulmonary Resuscitation (ECPR). The respiratory segment is estimated to account for the largest share of the market in 2016. The large share of this segment can be attributed to factors such as rising incidence of respiratory failure, lung cancer, and lung transplants, and increasing adoption of ECMO.

On the basis of region, the global ECMO machine market is divided into North America, Europe, Asia-Pacific, and the Rest of the World (RoW). In 2016, North America accounted for the largest share of the market, followed by Europe, Asia-Pacific, and the Rest of the World. The Asia-Pacific market is projected to grow at the highest CAGR and serve as a revenue pocket for companies offering ECMO systems.
 
Request For Sample Pages: http://www.marketsandmarkets.com/requestsample.asp?id=255167654

In 2015, the market was dominated by the Getinge Group (Sweden), Medtronic plc (Ireland), and LivaNova PLC (U.K.). These companies together contributed about 68.8% to the global market in 2015. The other players in the Extracorporeal Membrane Oxygenation Machine Market are XENIOS AG (Germany), Terumo Corporation (Japan), MicroPort Scientific Corporation (China), NIPRO Corporation (Japan), OriGen Biomedical, Inc. (U.S.), ALung Technologies, Inc. (Germany), and EUROSETS S.r.l. (Italy).

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Content Source: https://www.marketsandmarkets.com/PressReleases/extracorporeal-membrane-oxygenation-systems.asp

 

Life Science Analytics Market worth $42.0 billion by 2025 - Exclusive Report by MarketsandMarkets™

 According to the new market research report "Life Science Analytics Market by Type (Predictive, Descriptive, Prescriptive), Application (Marketing, Compliance, Clinical trial, R&D, Pharmacovigilance, SCM), Component (Software, Service), Delivery, End User, & Region - Global Forecast To 2025", published by MarketsandMarkets™, the global Life Science Analytics Market size is expected to reach 42.0 billion by 2025 from USD 22.1 billion in 2020, at a CAGR of 13.7% during the forecast period of 2020 to 2025.

Browse and in-depth TOC on "Life Science Analytics Market"

426- Tables

41- Figures

301- Pages

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=174990653

The Growth in this Pharmaceutical Analytics Software Market is mainly driven by technological advancements, big data in the life science industry, growing adoption of analytics solutions in clinical trials, increasing adoption of analytics for sales and marketing applications, need for improved data standardization, increasing prevalence of chronic diseases, growing pressure to curb healthcare spending, and the need for improved patient outcomes. On the other hand, high implementation costs are expected to restrain the growth of this market to a certain extent.

The on-demand model segment is expected to grow at the highest CAGR during the forecast period.

Based on the delivery mode, the Life Science Analytics Market is segmented into the on-demand model and the on-premise model. The on-demand model segment is expected to grow at the highest CAGR during the forecast period, owing to advantages such as increasing demand for self-driven analytics, lack of upfront capital investments for hardware, extreme capacity flexibility, and pay-as-you-go pricing of this model.

The descriptive analytics segment accounted for the largest market share in 2019.

Based on type, the market is segmented into descriptive analytics, predictive analytics, and prescriptive analytics. The descriptive analytics segment accounted for the largest share of the Pharmaceutical Analytics Software Market in 2019. The large share of this segment is attributed to the significant usage of descriptive analytics by stakeholders to gain a better understanding of the past trends and events occurring in real-time.

In 2019, North America accounted for the largest share of the market.

In 2019, North America accounted for the largest market share, followed by Europe. The large share of this market can primarily be attributed to the strong economies in the US and Canada, which have allowed for significant investments in technology in this region. Growth in the North American market is supported by the growing adoption of IT in the life science industry, rising pressure to reduce healthcare costs, stringent regulations for the pharma-biotech and medical device industries, and the greater product and service availability in this region.

Request For Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=174990653

The prominent players operating in the Life Science Analytics Market are Oracle Corporation (US), Accenture (Ireland), SAS Institute Inc. (US), IBM Corporation (US), Wipro (India), Cognizant (US), SCIO Health Analytics (US), Allscripts Healthcare Solutions (US), Cerner Corporation (US), IQVIA (US), Microsoft (US), Infosys Limited (US), MaxisIT (US), Optum (US), and Cotiviti (US).

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Content Source: https://www.marketsandmarkets.com/PressReleases/life-science-analytics.asp

Remote Patient Monitoring Market worth $117.1 billion by 2025

According to the new market research report “Remote Patient Monitoring Market by Product (Software, Services, Devices, Cardiology, Neurological, Blood Glucose, Neonatal, Weight, Temperature, Neuro) End User (Providers, Hospitals, Clinics, Home Care, Patients, Payers) – Global Forecast to 2025″, published by MarketsandMarkets™, the global RPM Market size is projected to reach USD 117.1 billion by 2025 from USD 23.2 billion in 2020, at a CAGR of 38.2% between 2020 and 2025.

Browse in-depth TOC on “Remote Patient Monitoring Market”

149 – Tables
34 – Figures
189 – Pages

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=77155492

The rising geriatric population and the growing need to expand healthcare access, cost benefits of telehealth and remote patient monitoring, benefits of RPM to reduce the burden on medical resources, advancements in telecommunications, growing incidences of chronic diseases, and increasing investments in telehealth and RPM are the major factors driving the growth of this market. However, the regulatory variations across regions, healthcare fraud, and informal usage of social media practices is expected to restrain the market growth during the forecast period.

Software and services to dominate the remote patient monitoring market in 2019

Based on the product, the RPM Market is segmented into software & services and devices. The software and services segment accounted for the largest share of the global market in 2019. The large share of this segment is mainly due to the increasing reimbursement for RPM programs and the rising number of chronic illnesses, thus leading to the growing adoption of RPM services across the globe.

Providers segment accounted for the largest share of the remote patient monitoring market, by end user, in 2019

Based on end users, the global market is broadly segmented into providers, payers, patients, and other end users. The providers’ segment accounted for the largest share of the global market in 2019. This can be attributed to the increased adoption of remote monitoring in chronically ill and old aged patients, advancements in RPM monitoring devices, and the increasing number of RPM services offered by providers.

North America is the largest regional market for remote patient monitoring in 2019

In 2019, North America accounted for the largest share of the remote patient monitoring market, followed by Europe. The large share of North America in the RPM Market can be attributed to the rising prevalence of chronic conditions, the need to reduce healthcare expenditure, and the increasing overall & geriatric population.

Request For Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=77155492

Prominent players in the remote patient monitoring market are BioTelemetry Inc. (US), Koninklijke Philips N.V. (Netherlands), Medtronic (Ireland), GE Healthcare (US), Cerner Corporation (US), Siemens Healthineers AG Germany, OMRON Healthcare (Japan), Boston Scientific Corporation (US), Abbott Laboratories (US), Resideo Life Care Solutions (US), Vivify Health, Inc. (US), ALTEN Calsoft Labs (France), Preventice Solutions (US), Bio-Beat Technologies (Israel), VitalConnect (US), Welch Allyn (US), Teladoc Health Inc. (US), Dexcom Inc. (US), iRhythm Technologies, Inc. (US), and VivaLNK Inc. (US).

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the “Growth Engagement Model – GEM”. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers,

write “Attack, avoid and defend” strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, “Knowledge Store” connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:

Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Content Source: https://www.marketsandmarkets.com/PressReleases/remote-patient-monitoring.asp

Cancer Biomarkers Market worth $20.4 billion by 2022

According to research report the Cancer Biomarkers Market was valued at USD 11.5 billion in 2017 and is estimated to grow at a CAGR of 12.2% during the forecast period, to reach USD 20.4 billion by 2022. The increasing prevalence of cancer, rising government support for research on cancer biomarkers, growing use of biomarkers in drug discovery and development, and increasing use of biomarker tests for diagnostic purposes are the major factors that are driving the growth of this market.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=202

Browse 268 market data Tables and 37 Figures spread through 249 Pages and in-depth TOC on "Cancer Biomarkers Market by Type (Protein Biomarker, Genetic Biomarker), Cancer Type (Breast, Melanoma, Leukemia, Lung), Profiling Technology (Omics, Imaging, Immunoassay, Bioinformatics), Application (Diagnosis, Prognostics, R&D) - Global Forecast to 2022"

The breast cancer segment accounted for the largest share of the cancer biomarkers market in 2016

Based on cancer type, the cancer biomarkers market is segmented into breast, lung, colorectal, prostate, melanoma, leukemia, thyroid, bladder, non-Hodgkins lymphoma, kidney, and other cancers (such as cervical, multiple myeloma, CNS, gastric, liver, pancreatic, oral cavity and pharynx, stomach, and ovarian cancers). The breast cancer segment accounted for the largest share of this market owing to the high and growing prevalence of breast cancer, increasing awareness about breast cancer, rising number of breast cancer screening programs, and growing research on breast cancer.

The genetic biomarkers segment is expected to grow at the highest CAGR during the forecast period

Based on biomarker type, the cancer biomarkers market is segmented into genetic biomarkers, protein biomarkers, and other biomarkers (cell, viral, and carbohydrate biomarkers). During the forecast period, the genetic biomarkers segment is estimated to grow at the highest CAGR majorly due to advancements in high-throughput technologies, such as next-generation sequencing, which have enhanced the speed and accuracy of genetic biomarker discovery and diagnosis.

North America was the largest regional market for cancer biomarkers in 2016

North America accounted for the largest share of the cancer biomarkers market in 2017, followed by Europe. North America is the largest market for cancer biomarkers majorly due to government support (in the US and Canada) for the discovery and development of biomarkers, rising use of biomarkers in drug discovery and development by pharmaceutical companies, adoption of advanced omics technologies for biomarker discovery, and the increasing demand for personalized medicine in the region.

Request For Report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=202

The major players operating in the cancer biomarkers market are Abbott (US), Affymetrix (US), Roche (Switzerland), Illumina (US), QIAGEN (Netherlands), Agilent (US), Thermo Fisher (US), Merck (US), Becton Dickinson and Company (US), and Hologic (US).

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Rohan
MarketsandMarkets™
701 Pike Street
Suite 2175, Seattle,
WA 98101, United States
Tel: +1-888-600-6441
Email: sales@marketsandmarkets.com
Content Source: https://www.marketsandmarkets.com/PressReleases/oncology-biomarkers-market.asp

ECG Market Worth $10.3 Billion by 2024

According to the new market research report “Diagnostic Electrocardiograph Market By Product (Resting ECG, Stress, Mobile Cardiac Telemetry Device, Implantable Loop Recorder) and Service, By Lead Type (12-lead, 6-lead, 5- lead), End User, and Region – Global Forecast to 2024″, published by MarketsandMarkets™, the global Diagnostic Electrocardiograph Market is expected to reach USD 10.3 billion by 2024 from USD 7.5 billion in 2019, at a CAGR of 6.4% during the forecast period.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=173

The Factors such as the rising incidence of lifestyle & cardiovascular diseases and increasing geriatric population are expected to propel the growth of the market.

The hospitals, clinics, and cardiac centers segment accounted for the largest share of the Diagnostic Electrocardiograph (ECG) Market in 2018

By end user, the market is classified into hospitals, clinics, and cardiac centers; ambulatory surgical centers; and other end users. In 2018, the hospitals, clinics, and cardiac centers segment accounted for the largest share of the market. The large share of this segment can primarily be attributed to the growing burden of cardiovascular diseases, which, in turn, is increasing the need for quality cardiology care.

Browse in-depth TOC on “Diagnostic Electrocardiograph (ECG) Market”

127 – Tables

27 – Figures

142 – Pages

The 3-lead ECG segment is expected to grow at the highest CAGR in the diagnostic ECG market during the forecast period

By lead type, the diagnostic ECG market is divided into 12-lead, 5-lead, 3-lead, 6-lead, single-lead, and other lead types (15- and 18-lead). The 3-lead segment is expected to grow at the highest CAGR during the forecast period. This positive growth is primarily due to the fact that these leads are used conjointly with various other cardiac diagnostic tests and during medical procedures.

Asia Pacific diagnostic ECG market is expected to grow at the highest CAGR during the forecast period

On the basis of region, the diagnostic ECG market is segmented into North America, Europe, Asia Pacific, and RoW. The Asia Pacific is expected to grow at the highest CAGR during the forecast period. Factors such as growth in the geriatric population, growing incidence of chronic diseases, rising healthcare spending, healthcare reforms for infrastructural development, growing demand for advanced technologies, and less stringent regulations are fueling the demand for diagnostic ECG products and services in this region.

Request For Report Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=173

Market Players:

The Diagnostic Electrocardiograph (ECG) Market is dominated by players such as GE Healthcare (US), Philips Healthcare (Netherlands), Nihon Kohden (Japan), Hill-Rom Holdings (US), and Ambu (Denmark).

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the “Growth Engagement Model – GEM”. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write “Attack, avoid and defend” strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, “Knowledge Store” connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Content Source: https://www.marketsandmarkets.com/PressReleases/Diagnostic-ECG.asp